HIV-infected individuals on long-term antiretroviral therapy are at higher risk for ocular disease

被引:9
|
作者
Schaftenaar, E. [1 ,2 ]
Khosa, N. S. [2 ]
Baarsma, G. S. [3 ]
Meenken, C. [4 ]
Mcintyre, J. A. [2 ,5 ]
Osterhaus, A. D. M. E. [6 ]
Verjans, G. M. G. M. [1 ,6 ]
Peters, R. P. H. [2 ,7 ]
机构
[1] Erasmus MC, Dept Virosci, Rotterdam, Netherlands
[2] Anova Hlth Inst, 12 Sherborne Rd, Johannesburg, South Africa
[3] Rotterdam Ophthalm Inst, Rotterdam, Netherlands
[4] Vrije Univ Amsterdam, Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands
[5] Univ Cape Town, Sch Publ Hlth & Family Med, Cape Town, South Africa
[6] Univ Vet Med, Res Ctr Emerging Infect & Zoonoses, Hannover, Germany
[7] Univ Pretoria, Dept Med Microbiol, Pretoria, South Africa
来源
EPIDEMIOLOGY AND INFECTION | 2017年 / 145卷 / 12期
关键词
ART; HIV; ocular disease; rural South Africa; IMMUNE-DEFICIENCY-SYNDROME; GENERAL-POPULATION; ANTERIOR SEGMENT; CATARACT-SURGERY; DRY EYE; MANIFESTATIONS;
D O I
10.1017/S0950268817000978
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction of antiretroviral therapy (ART) has dramatically reduced the incidence of infectious ocular diseases in human immunodeficiency virus (HIV)-infected individuals. However, the effects of long-term ART and chronic HIV infection on the eye are ill-defined. This study determined the occurrence and severity of ocular diseases among 342 participants in a rural South African setting: HIV-naive (n = 105), HIV-infected ART-naive (n = 16), HIV-infected on ART for < 12 months (short-term ART; n = 56) and HIV-infected individuals on ART for > 36 months (long-term ART; n = 165). More HIV-infected participants presented with an external eye condition, in particular blepharitis, than HIV-naive individuals (18% vs. 7%; age-adjusted odds ratio (aOR) = 2.8, P < 0.05). Anterior segment conditions (particularly keratoconjunctivitis sicca and pterygium) were also more common (50% vs. 27%; aOR = 2.4; P < 0.01). Compared with individuals on short-term ART, participants receiving long-term ART were more likely to have clinically detectable cataract (57% vs. 38%; aOR = 2.2, P = 0.01) and posterior segment diseases, especially HIV retinopathy (30% vs. 11%; aOR = 3.4, P < 0.05). Finally, long-term ART was significantly associated with presence of HIV retinopathy (P < 0.01). These data implicate that ocular disease is more common and of more diverse etiology among HIV-infected individuals, especially those on long-term ART and suggest that regular ophthalmological monitoring of HIV-infected individuals on ART is warranted.
引用
收藏
页码:2520 / 2529
页数:10
相关论文
共 50 条
  • [41] Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy
    Mark J. Bolland
    Anne M. Horne
    Simon E. Briggs
    Mark G. Thomas
    Ian R. Reid
    Greg D. Gamble
    Andrew Grey
    Calcified Tissue International, 2019, 105 : 423 - 429
  • [42] The Effect of Polymorphisms in Candidate Genes on the Long-Term Risk of Lipodystrophy and Dyslipidemia in HIV-Infected White Patients Starting Antiretroviral Therapy
    Marzocchetti, Angela
    Schwarz, Jessica
    Di Giambenedetto, Simona
    Colafigli, Manuela
    Bracciale, Laura
    Fabbiani, Massimilliano
    Fantoni, Massimo
    Trecarichi, Enrico
    Cauda, Roberto
    De Luca, Andrea
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (12) : 1300 - 1310
  • [43] Ocular Tuberculosis in HIV-infected Individuals
    Mehta, Salil
    Peters, Remco P. H.
    Smit, Derrick P.
    Gupta, Vishali
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (08) : 1251 - 1258
  • [44] Lack of association between antiretroviral therapy and predictors of endothelial function and cardiovascular disease (CVD) risk among HIV-infected persons on long-term HAART
    Mandy, K.
    de las Fuentes, L.
    Onen, N.
    Waggoner, A.
    Bopp, C.
    Lasso-Claxton, S.
    Davila-Roman, V.
    Yarasheski, K.
    ANTIVIRAL THERAPY, 2007, 12 (06) : L38 - L39
  • [45] Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy
    Barreiro, P
    de Mendoza, C
    Camino, N
    García-Benayas, T
    Blanco, F
    Núñez, M
    González-Lahoz, J
    Soriano, V
    HIV CLINICAL TRIALS, 2003, 4 (06): : 361 - 371
  • [46] Audiological and electrophysiological alterations in HIV-infected individuals subjected or not to antiretroviral therapy
    Matas, Carla Gentile
    Samelli, Alessandra Giannella
    Leite Magliaro, Fernanda Cristina
    Segurado, Aluisio
    BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, 2018, 84 (05) : 574 - 582
  • [47] The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals
    Ray, Maile
    Logan, Roger
    Sterne, Jonathan A. C.
    Hernandez-Diaz, Sonia
    Robins, James M.
    Sabin, Caroline
    Bansi, Loveleen
    van Sighem, Ard
    de Wolf, Frank
    Costagliola, Dominique
    Lanoy, Emilie
    Bucher, Heiner C.
    von Wyl, Viktor
    Esteve, Anna
    Casabona, Jordi
    del Amo, Julia
    Moreno, Santiago
    Justice, Amy
    Gouler, Joseph
    Lodi, Sara
    Phillips, Andrew
    Seng, Remonie
    Meyer, Laurence
    Perez-Hoyos, Santiago
    de Olalla, Patricia Garcia
    Herman, Miguel A.
    Phillips, A. N.
    Gilson, R.
    Easterbrook, P.
    Fisher, M.
    Gazzard, B.
    Johnson, M.
    Walsh, J.
    Leen, C.
    Orkin, C.
    Anderson, J.
    Pillay, D.
    Delpech, V.
    Schwenk, A.
    Dunn, D.
    Gompels, M.
    Hill, T.
    Porter, K.
    Babiker, A.
    Sabin, C.
    AIDS, 2010, 24 (01) : 123 - 137
  • [48] Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy
    Gerber, MT
    Mondy, KE
    Yarasheski, KE
    Drechsler, H
    Claxton, S
    Stoneman, J
    DeMarco, D
    Powderly, WG
    Tebas, P
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (03) : 419 - 425
  • [49] Kaletra® (lopinavir/ritonavir), an antiretroviral therapy for HIV-infected individuals.
    Sham, HL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U1186 - U1186
  • [50] Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine
    DeSilva, KE
    Le Flore, DB
    Marston, BJ
    Rimland, D
    AIDS, 2001, 15 (10) : 1281 - 1285